Life sciences mergers and acquisitions (M&A) activity gained momentum in late 2025, and that acceleration is expected to continue in 2026. This positive trend is vitally important for the many treatments and cures that depend on these partnerships to reach patients.
M&A plays a unique and critical role in America’s life sciences ecosystem by:
- Connecting early-stage discoveries to the clinical, manufacturing, and regulatory capabilities required to advance drug development and commercialization.
- Incentivizing investment in the next generation of companies and therapies, by serving as a clear and anticipated exit point for investors.
- Ensuring that scientific breakthroughs reach patients as quickly and efficiently as possible. Drugs in development that undergo M&A are nearly twice as likely to launch compared to non-acquired drugs.
Against this backdrop, renewed dealmaking is a promising signal for the health and resilience of the U.S. life sciences ecosystem. However, some analysts have cautioned that regulatory and policy unpredictability could impede this momentum and the innovative new treatments it supports.
For life sciences companies already operating in a high-stakes environment, added uncertainty can be uniquely disruptive. Consider that:
- Roughly 80% of life science companies operate without a profit.
- Nearly 90% of drug candidates fail to reach the market.
- Bringing a single therapy to market can take 10-15 years and cost more than $2.6 billion.
Unpredictable M&A enforcement can delay or deter the pro-competitive partnerships that help companies navigate this long, high-risk journey. By contrast, predictability fuels innovation. Clear and consistent M&A enforcement enables companies to invest with confidence in the next generation of therapies, engage in pro-competitive partnerships, and, ultimately, bring new lifesaving medicines to patients. To sustain the renewed momentum behind life sciences M&A in 2026 – and ensure that patients continue to benefit from medical and scientific progress – policymakers must prioritize predictability and balance in life sciences M&A enforcement.